EGFR and non-small cell lung carcinoma: In Japan, the median PRS of recurrent NSCLC was reported to be 17.7–25 months (2–4); thus, it was shown that EGFR mutation‐positive patients were expected to achieve very long survival, even if they developed postoperative recurrence.